WEEKLY WRAP-UP

03RD AUGUST - 07TH AUGUST 2026

PROGRESSIVE®
Your Progress Our Priority...

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

DOMESTIC:

- Bank of Maharashtra cuts home loan rate to 7%, waives processing fee
- Coal India's July supplies jump 18.4% y-o-y to record 64.19MT
- Tata Steel gets nod for trial restart of Dutch mill
- Vikram Solar plans Rs16,000cr expansion
- Voda Idea receives Rs26.8cr notice from DoT over spectrum rollout
- ICICI Lombard shifts focus from risk transfers to risk management
- ITC completes Century Pulp acquisition, expands paper business scale
- Essar to invest USD5.8bn in UK energy transition projects by 2035
- Hero doubles down on premium segment amid weak sales
- Ather becomes first new-age EV 2W maker to achieve Ebitda breakeven
- Airtel sees USD3-4bn annual capex, bets on post-paid to monetize 5G
- L&T bags ultra-mega project order from ADNOC Offshore
- Persistent Systems upbeat on banking, insurance to drive growth: CEO
- Nestlé India says long-term growth intact despite demand concerns
- Vedanta faces fresh scrutiny over 'illegal' groundwater extraction
- Takeda bets on dengue vax to reshape India playbook
- JSW, VW group plan new set of wheels to drive JV
- Marico to prioritise margins over volumes in certain segments
- USFDA issues warning letter to Dabur over CGMP lapses at Silvassa plant
- Airtel widens value lead over Jio with premiumisation push
- TVS Motor consolidates lending businesses under TVS Credit
- Natco challenges Novartis's second patent for cancer drug ribociclib in Delhi HC
- DLF eyes Rs1lk-cr sales pipeline in 4-5 yrs, rules out REIT for now
- ONGC set to revive operations in Venezuela
- Berger Paints sees strong demand, monsoon driving growth in FY27
- PNB Housing targets Rs100cr micro-housing loan book in FY27
- Emami to invest Rs400cr in Bengal food park, eyes Agrotech IPO
- JSW Energy RE arms borrow Rs4,000cr from banks, NaBFID

ECONOMY:

- FPIs reverse 4-month selling trend with Rs20,200cr inflow in July
- US crude inventories rise as refinery runs ease and imports climb: EIA
- RBI plans to roll out polymer banknotes by FY28

INDUSTRY:

- Global FMCG majors to boost investments in India, widen retail presence
- India PV sales hit record high in July, up 34% on strong demand and GST cuts
- Govt. hikes export duty on diesel to Rs25.5 per litre, ATF to Rs22 amid oil volatility

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

COVERAGE NEWS:

Gland Pharma Ltd: The company has announced long term strategic CDMO partnership with Neuland Laboratories for sterile API manufacturing.

Alkem Laboratories Ltd: The USFDA has classified the inspection status (earlier received 7 observations) of the company's facility at Daman as OAI.

KSB Ltd: The company has purchased a new land adjacent to the existing Shirwal plant. The proposed shed is intended for manufacturing of project pumps and is expected to add a capacity of 20%. The tentative investment needed is Rs400mn to be funded via internal accruals.

Cipla Ltd: The manufacturing facility of InvaGen Pharmaceuticals, Inc. located in New York has received an EIR from the USFDA, indicating the closure of the inspection.

Texmaco Rail & Engineering Ltd: The company has executed an MoU with Škoda Digital S.R.O., to explore the potential for business opportunities in the field of railway digitalization solutions.

The Week That Went By:

Nifty50 began August on a strong note, breaching the key resistance level of 24,525. However, despite the breakout, the Index failed to sustain its momentum and traded within the 24,530–24,670 range for the remainder of the week, eventually closing at 24,570.65, up 187.05 points. PSU Banking was the top-performing segment, followed by Defence and Autos. On the other hand, the Media was the biggest laggard, followed by the Capital Market Index. In the Broader market, Midcaps largely moved in line with the Frontline Index, while Smallcaps outperformed, gaining 2.73%.

Nifty50=24,570.65 **Sensex30=78,499.17** **Nifty Midcap 100=63,463.55** **Nifty Smallcap100=19,867.80**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Aurobindo Pharma Ltd **CMP: Rs1661** **Target: Rs1865**	The net sales for the quarter reported a growth of 16.3% to Rs91.50bn as compared to Rs78.68bn in Q1FY26. The Ebitda margins for the quarter under review stood at 20.6% as compared to 20.4% in Q1FY26. The company reported profit of Rs10.32bn as compared to Rs8.24bn in the same quarter last year. The EPS for the quarter stood at Rs17.86 as compared to Rs14.20 in the corresponding period of last year. **Outlook and Recommendations:** The company has beaten estimates on both the headline numbers led by broad-based growth during the quarter. The revenue growth stood at 16.3% y-o-y led by healthy growth across businesses through disciplined execution, operational excellence, and the continued strength of the diversified product portfolio. The Ebitda margins stood at 20.6% for the quarter. The other expenses have a component of net loss of Rs432.6mn related to derecognition of lease receivable; adjusting for which the Ebitda margins stood at 21%. While operating margins expanded modestly, the bottom line benefited significantly from other income, which nearly doubled to Rs2,642mn from Rs1,053mn in Q1FY26, alongside **a foreign exchange gain** of Rs526mn. The lower R&D expenses also supported profitability. The overall profits have reported growth of 25.2% y-o-y; backed by the double-digit growth across key markets, improved operating performance and new product launches. The **US formulations** revenue increase of 8.1% y-o-y was primarily driven by volume gains and new launches, partially offset by no transient product sales. The launch of its high-potential **gAdvair** alternative remains on track for August. Three US biosimilar filings are expected within one quarter. The company has successfully closed its ~USD247mn acquisition of **Lannett Company LLC**, which is expected to support near-term US solid oral formulations momentum. It offers large unutilized capacity (operates at 40%) to launch previously uncommercialised products; with Management targeting optimized levels within 12 months. **Europe** emerged as the strongest-performing major geography, with revenue growth of 25.6% y-o-y, accounting to 32.1% of consolidated revenues. The company attributed the growth to robust demand across its key European markets. Going forward, it expects double digit growth for the year. The **growth markets** recorded a growth 37.7% y-o-y which included domestic sales of Rs1040mn. The **API** segment reported growth of 14.5% y-o-y despite sequential seasonal softness in the antibiotics' portfolio. **ARV** revenue remained stable at Rs3300mn for the quarter. The **Eugia** injectables arm expects single-digit growth due to fewer new approvals; FY27E revenue is guided at USD500mn. In terms of the **biosimilar** launches; they are off to a steady start. The TheraNym CMO platform expects initial revenues by 2028. The Management projects a combined revenue of USD150-200mn from Units 1 and 2 by 2032. In a **major corporate move**, the Board has also approved a scheme to merge step-down sterile and SEZ injectables units into a single corporate subsidiary. This not only optimizes cost and compliance structures but also positions the premium injectables platform cleanly for potential future value unlocking or a standalone strategic listing. **China** OSD facility currently houses an annual capacity of **over 2 billion tablets** and is ramping up but remains unprofitable; while Ebitda is expected to turn positive later this fiscal year. In terms of **guidance**, the Management aims for absolute Ebitda to be Rs80bn in FY27E and margins to be north of 21%. The revenues are expected to clock double digit growth for the year. The Management also said it is targeting a quarterly revenue run rate of about Rs22bn, though it noted that geopolitical conditions in the Middle East could affect the pace. The company has generated USD98mn in **free cash flow** despite significant capital outflows for the Lannett acquisition and share buybacks. The company has highlighted that a decade of major investments is hitting an inflection point; strategic pivot from heavy investments to milestone monetization. The Management expects 2029 to be the primary revenue inflection year. Some of the **key monitorables** include the reinspection and resolution of the OAI status at Eugia Unit-III and Unit-I by the USFDA, revenue scale-up and margin contribution from the newly integrated Lannett Company LLC acquisition and successful commercialization and qualification milestones at TheraNym's Biologics contract manufacturing Unit-1. **We maintain accumulate on the stock for a revised target of Rs1865.**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Torrent Pharmaceuticals Ltd **CMP: Rs4952** **Target: Rs5500**	The net sales for the quarter reported a growth of 54.8% to Rs49.21bn as compared to Rs31.78bn in Q1FY26. The Ebitda margins for the quarter stood at 33.8% as compared to 32.5% in the comparative quarter last year. The company reported profit of Rs5.66bn as compared to Rs5.48bn in the same quarter last year. The EPS for the quarter stood at Rs14.87 as compared to Rs16.19 in the corresponding period of last year. **<u>Outlook and Recommendations:</u>** The company reported better than expected numbers for the quarter under reference led by growth across the DF segment as well the momentum in the US generics space; covering up the drag by performance across the Brazil and Germany markets. This marks the 1st quarter for Torrent which includes the integrated numbers from JBPCL (the merger became effective from 8th July 2026). The overall sales registered a growth of 54.8% on a y-o-y basis. The base business for Torrent reported a growth of 17% on a y-o-y basis. The combined **India business** registered a growth of 60% on a y-o-y business which includes JBCPL revenues of Rs7330mn; ex-JBCPL as well the India base business for Torrent reported a good growth of 19% on a y-o-y basis which was categorised as 5.1% volume (2% market), 7.7% price (5.8% market) and 6.0% new products (3.8% market). The company has outperformed the IPM by almost 700bps through a combination of growth in price, volume and new launches. Alongwith with increase in IPM growth, the new launches and volume growth acceleration from field force expansion were also the prime reasons. The Curatio portfolio saw strong 34% y-o-y growth, partly driving overall DF growth for the quarter. Going forward, the Management continues to outpace the industry growth for the India business. With regard to JBCPL, the Management expects to focus on merging the divisions alongwith transfer of brands to Torrent over the next 6-9 months (the next stage of integration) and this may have some minor impact in revenues in certain territories until this integration process is completed. The cost synergy has already started showing benefits in margin of JB Chem business, with ~35% Ebitda margins achieved in Q1FY27. The cost synergies from JB Chem acquisition are tracking ahead of plan, with Management indicating FY27E synergy realization to exceed the initial Rs900mn target and surpass Rs1.0bn. The Management expects small, temporary revenue disruption over the next 2-3 quarters due to JB Chem brand consolidation in India and portfolio rationalization in select international markets; sales are expected to normalize and revive after the integration. It has reiterated double-digit revenue growth for the combined India (JB) business in FY27E, while the international business of JB Chem is expected to recover after integration-related changes.For the **US business**, the revenues grew by 36% on a y-o-y basis whereas in dollar terms they stood at USD44mn. The **Brazil** sales grew by 27% on a y-o-y basis though on a constant currency terms the revenues were more or less flat which was on account of channel inventory correction undertaken in Q1FY27. On the financial front, the favourable factors that led to an improvement in the gross margins was attributed to price increase (annual), higher contribution from India branded business and positive forex. The Management has deferred the full year guidance for the combined business for now until the next stage of integration progresses. Torrent would vouch for opportunities in the Indian markets as and when required but may also consider a mid-sized international acquisition if no attractive domestic deal favours the business operations. Overall, given the integration and synergy processes already started reflecting in Torrent's business coupled with strategies aligned for each of the geographies that the company caters to, Torrent is decently positioned to pace up the growth over a medium to long-term perspective. **In the current juncture, with valuations factoring most of the rationales, we recommend booking 20% profits and maintain hold on the stock for a revised target of Rs5500 (earlier target of Rs5000 has been breached).**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Bharat Bijlee Ltd **CMP: Rs2346** **Target: Rs2700**	The net sales for the quarter reported a growth of 17.7% to Rs5,472mn as compared to Rs4,649mn in Q1FY26. The Ebitda margins for the quarter stood at 5.3% as compared to 7.2% in the comparative quarter last year. The company reported profit of Rs196mn as compared to Rs279mn in the same quarter last year. The EPS for the quarter stood at Rs17.3 as compared to Rs24.6 in the corresponding period of last year. On the segmental front, the Power division reported a marginal growth of 3% on a y-o-y basis and drop of 46.7% on a q-o-q basis whereas, Industrial division reported a growth of 37.3% and 8.1% on a y-o-y and q-o-q, respectively. **<u>Outlook and Recommendations:</u>** The Indian electrical equipment and transformer industry is experiencing a massive tailwind driven by public and private capex in power transmission and green energy. Players like BBL are critical suppliers to national infrastructure projects. However, industry-wide volatility in commodity prices like copper, CRGO steel, and aluminium continues to pose margin risks for transformer manufacturers. For Q1FY27, BBL has reported revenue growth of 17.7% y-o-y with profitability continuing to be under stress. The margins have come lower at 5.3% for the quarter largely due to higher expenses (input and operating costs); which the company has not been able to pass on to its customers, denting the profits with a drop of 29.6% y-o-y. With regard to the **segmental** performance, the **power** segment (majorly includes transformers, turnkey projects for electrical sub-stations and maintenance products) revenues grew by 3.0% y-o-y while the **industrial** segment (includes electric motors, drives & automation systems and magnet technology machines), revenues grew by 37.3% y-o-y. BBL continues to be the conductor of the electrical orchestra; electrical engineering being the key to strong growth across major sectors with its offerings being power transformers, switchyards, electric motors, drives & automation systems and permanent magnet technology machines to name a few. It is one of the leading players in the domestic transformer as well as the electrical motor industry and receives repeat orders from various SEBs and private players, along with a healthy retail presence in the motors segment. In terms of **power systems**, the market has been growing at 15% 3-year CAGR, while BBL has been faster than market growth with CAGR of 25%. Different players across the segment are aggressively expanding capacities which would lead to pricing pressures going ahead. Capex for this segment is chalked at Rs2200mn; with the largest expansion in transformer industry being undertaken; expected to be completed by Q4FY27, and should lead to higher revenues in couple of years. As indicated earlier, the company had embarked on capacity expansion of transformer manufacturing facility at its Airoli works to increase the current capacity of 18000MVA to 28000MVA at a capital outlay of about Rs1700mn, to be funded out of internal accruals. The **transformer business** continues to focus on diversifying and widening its customer base across the national geographies to complement the strong base in public electricity utilities. In the **Industrial** segment, **Motor** business continues to be a segment of focus where product development across sectors like water management and coal mining is gathering steam. The **pending order book** as of Jun'26 stands as, Motors at Rs2930mn, Drives/Automation is Rs190mn, MTM at Rs100mn and projects at Rs1250mn; taking the cumulative outstanding orderbook to Rs24,480mn. In terms of the **guidance** for FY27E, the order book is extending visibility for business, if the geopolitical scenario remains stable alongwith supply chain of engineering products, FY27E is expected to be a good year for the company. Overall, BBL is continuously investing resources in enlarging its technologically advanced, superior, and sustainable product offerings and in augmenting its facilities to capitalise on emerging opportunities. In order to factor in the recent operational pressure being faced we have tweaked our numbers and **recommend a hold on the stock for a revised target of Rs2700.**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Thermax Ltd **CMP: Rs4054** **Target: Rs4600**	The net sales the quarter under review grew by 6.7% to Rs23.03bn as compared to Rs21.58bn in Q1FY26. The Ebitda margins for the quarter under review stood at 3.0% as against 10.4% in Q1FY26. The net profit came in at Rs0.22bn as against Rs1.52bn in the comparative quarter last year. The EPS for the quarter under review stood at Rs2.24 as against Rs13.53 in Q1FY26. On the segmental performance, industrial products segment revenue grew by 11.37% on a y-o-y basis to Rs10.58bn, while industrial infra segment revenue de-grew by 2.79% to Rs8.14bn, green solutions advanced by 2.97% on a y-o-y basis to Rs2.30bn and chemical segment revenue came in at Rs2.30bn, soared by 32.54% on a y-o-y basis. **Outlook and Recommendations:** Thermax's first quarter was marked by a sharp contrast between its pipeline and its execution results. Management said the company had a significant backlog, but revenue growth was limited by shipping delays and project timing. The current quarter's results witnessed Rs910mn Ebitda impact due to increase in the estimated cost to complete one specific project in the Industrial Infra segment, arising from events identified during the quarter. In addition, the corresponding quarter of the previous financial year included Rs560mn income under the Package Scheme of Incentives for a subsidiary in the Industrial Infra segment. Lower export sales also impacted the profitability of Industrial Products segment during the current quarter. Chemicals segment profitability is improved due to higher volumes and better product mix. The Green Solutions business incurred project overrun costs during the quarter, impacting margins. The revenues reported growth of 6.7% y-o-y with margins at 3% for the quarter; translating into PAT drop of 85.6% y-o-y. The industrial products segment reported growth of 11.3% to Rs10.58bn. Lower export sales also impacted the profitability of the segment during the current quarter. During the quarter, the company secured an order worth more than Rs4bn for the supply of boiler pressure parts for a data centre project in the US. The industrial infra segment reported a drop of 2.79% y-o-y, impacted by cost over runs in one project. The green solutions revenue grew by modest 3% for the quarter. The chemicals segment reported strong growth of 32.5% y-o-y. The orders intake was weak during the quarter (up by 2% y-o-y) but there is significant opportunity across the board and it is expected to exceed last years' OB with strong pipeline in progress. As of 30th June, 2026, the order balance for the quarter was Rs140.45bn, up ~23.4% from the corresponding quarter of the previous year. Of the total OB balance, only about Rs3bn is govt related; which is less than 5% and could also be zero going forward if not as per terms and pricing set by the company. The company said it is now reducing exposure to government and PSU work, which it described as less attractive because of pricing pressure, tougher contract terms and weaker customer relationships. The key govt projects include the one from IOCL worth Rs600mn and another one related to green methanol for Kandla project worth Rs1bn. Despite of hit in Q1, the Management is bullish on the business ahead betting on the strong order pipeline/backlog. It needs to do better in govt projects with the last year of exposure to the existing ones. It indicated of a run-rate of Rs30,000mn in the next 3Qs to meet its targets. Some margin pressure is expected in the industrial products segment in Q2, but overall, the year is expected to be good. The overall Ebitda margins are expected to improve compared to Q1 with no onetime costs expected going forward. In terms of the industrial products, the company was unable to ship finished goods to the tune of Rs3bn due to higher shipping rates and thereby the international customers delaying deliveries of parts. This is expected to flow in the quarters ahead. There was also commodity price impact of Rs100mn during the quarter. Growth areas such as data centers, hydrogen, green methanol and TOESL remain central to the company's long-term plan. In terms of the strategic initiatives, the management has highlighted (i) two additional data center cooling wins expected in the second half of FY27E, (ii) A hydrogen project announcement is expected in Q2, with revenue likely in FY28E, (iii) A green methanol project at Kandla Port is expected to execute from Q4FY27 to Q1FY28, (iv) Bio-CNG policy changes could lift economics if the government raises prices and expands mandates. **We had recommended 20% profit booking at Rs4650 and maintain hold for a revised target of Rs4600.**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Paushak Ltd **CMP: Rs704** **Target: Rs765**	The company has reported net sales of Rs836mn as compared to Rs559mn in the same quarter last year, growth of 49.5%. The Ebitda margins for the quarter under review stood at 30.70% as compared to 31.93% in Q1FY26. The net profit came in at Rs151mn as against Rs120mn in the same quarter last year. EPS for the quarter under review stood at Rs6.13 as compared to Rs4.88 in the corresponding quarter last year. **<u>Outlook and Recommendations:</u>** Paushak has started repositioning itself from a niche/spot-market chemical manufacturer to a long-term, relationship driven specialty chemicals or CDMO player. The company continues to tackle near term risks like volatility in raw material prices due to geopolitical tensions, Chinese dumping, pricing pressure and margin dilution as product mix keeps shifts with opportunities. The company operates across pharma, agrochemicals, polymers and specialty applications where many products enjoy market leadership positions. The business mix consists of Pharma contributing ~60% of the total revenues and the share of the agro products is expected to increase with the launch of new products. The company operates in a highly diversified downstream portfolio across multiple industries where ~70% of the phosphene capacity is currently utilized. The new facilities have stabilized and the benefits of the same are reflected in Q1FY27 volume growth. Capacity is available and the Management expects further optimization in the long term. The current capex cycle is aimed at modernising and replacing the aged infrastructure and also for creation of downstream capacity for future growth. Nearly half of the capex was undertaken to replace the old facilities and upgrade safety standards, while the balance was directed towards downstream capacity expansion; ~Rs1750mn has been invested in downstream manufacturing assets. The incremental returns will depend on the ramp up and successful commercialization of new products. The benefits of these investments are anticipated to become visible gradually. The company also emphasized that it is consistently working towards process improvements, yield enhancement and technology upgrades for better throughput efficiencies. The borrowings stand at ~Rs750mn and the debt-equity remains comfortable. Paushak is becoming a preferred partner in global supply chain diversification and CDMO while focusing on improved safety systems, better infrastructure, enhanced quality standards and stronger technical capabilities. As mentioned in our previous notes, the company is consistently working on larger volume agrochemical and CDMO segments where the operating margins are anticipated to decline; however, the absolute profits may increase. The future value creation is expected to depend on scale and asset turns rather than maintaining historical margins. The Management expects the incremental asset turns of ~0.8-1.25x. The Management is working towards reducing the exposure to commoditized markets and is focussing on fetching long term customer relationships with higher earnings visibility. As the new facilities begins to contribute revenue, the overall asset utilization is likely to improve with all the triggers mentioned above and so will the bottomline too will increase with time. **The stock has recently breached our target price to Rs625 and the scale of operations is expected to improve in the long term; we upgrade the same to Rs765.**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Sun Pharmaceutical Industries Ltd **CMP: Rs1949** **Target: Rs2200**	The total revenue grew by 10.5% to Rs152.99bn as compared to Rs138.51bn in the same quarter last year. The Ebitda margin for the quarter stood at 28.9% as against 31.1% in the corresponding quarter of last year. The company reported a net profit of Rs28.95bn as compared to Rs22.79bn in the comparative quarter. The EPS for the quarter under review stood at Rs12.10 as against Rs9.50. **Outlook and Recommendations:** The company has reported decent set of numbers for the quarter under review with a revenue growth of 10.5% on a y-o-y basis. Performance during the quarter was led by strong momentum in the India business and the innovative medicine business growth across US and other international markets. The **improvement** in the **gross margins** was on account of better product mix that was seen in the branded generics business as well as innovative medicines business despite the pricing pressure in the US generics market. The Ebitda margins stood at 28.9% for the quarter as against 31.1% in Q1FY26; however, there has been a sequential improvement reported. The margins were slightly on the lower side due to the benefits from lenalidomide sales that were factored in Q1FY26; adjusting for the same the margins would have been higher on a y-o-y basis. The PAT reported a growth of 27% on a y-o-y basis; however, adjusting for the one-offs, the overall PAT ended the quarter on a flat note at Rs30.98bn. Additionally, the higher tax outgo too weighed on the profitability to some extent. **India** sales reported a growth of 16% on a y-o-y basis led by a combination of factors that included field force expansion of the past, good performance across all the therapies (CVD, CNS, gastro-ortho) and volume growth alongwith new launches (accounted for 50% of the growth). The **US business** reported a drop of ~9.7% on a y-o-y basis and ~7% on a q-o-q basis which was largely due to the decline seen in lenalidomide sales and also additional competition seen in certain products couple with weakness in the generics business. The global **Innovative medicines** sales stood at USD351mn, up 12.8% on a y-o-y basis; the performance was led by traction seen in the US as well as the non-US markets. The Management expects the innovative business to continue to grow at a healthy rate going forward as well which would be led by new launches in the US markets alongwith a good traction seen in the already existing drugs such as Unloxcyt and Ilumya. The company highlighted recent approvals for semaglutide products in India, Brazil and South Africa as evidence of its capabilities in developing complex peptide products, where SUNP is already no. 2 generic player for the Indian markets and expects to maintain the leadership position whereas in South Africa the company has already launched the product and for Brazil the company is well positioned to commercialise the same. The **Emerging markets** revenues stood at USD311mn for the quarter under review while the **RoW** sales were flat at USD218mn; growth was slightly impacted on account of geopolitical headwinds alongwith macro related challenges in certain countries. The Management **retains its guidance** for the overall sales growth for FY27E at high single digits. The recently launched drugs viz; Unloxcyt and Leqselvi are gaining traction in the prescriber base, physician adoption and addition of more cancer centers. Even though the initial launch related costs are exhausted the Management expects certain costs to be incurred which would be a part of the other expenses component for these drugs during their commercialisation phase. The **Organon** deal is on track for closure by Q4FY27. Overall, the company is aptly placed for various growth triggers across the geographies. **We thus continue to maintain an accumulate on the stock for a revised target of Rs2200.**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Divi's Laboratories Ltd **CMP: Rs8249** **Target: Rs8500**	The net sales for the quarter reported a growth of 27.8% to Rs30,800mn as compared to Rs24,100mn in the same quarter last year. The Ebitda margins for the quarter stood at 40.7% as compared to 30.2% in the comparative quarter last year The company reported net profit of Rs9,020mn as compared to Rs5,450mn in the same quarter last year. The EPS for the quarter stood at Rs33.95 as compared to Rs20.49 in the corresponding period of last year. **Outlook and Recommendations:** Despite a challenging external environment on account of global trade routes and sourcing channels, the company has reported better than expected quarter with topline growth of 27.8% on a y-o-y basis. In terms of raw material availability, the same appears to be largely stable for Divis. Prices of certain raw materials have moderated during the quarter under review; the prices of solvent costs continued to remain at high levels and at present is highly dynamic and volatile. The Management has engaged itself closely with the customers in order to evaluate and try and mitigate these cost pressures wherever possible. The same is evident with a significant improvement seen on the **gross margins** which was reported at 68% during the quarter under review as against 60% in Q1FY26; highest in the last 20 quarters. The company continues to maintain enough inventory provisioning to derisk itself from any supply related disruptions and is well insulated with all the production and customer commitment schedules. The **Ebitda margins** have stood strong at 40.7% which was attributed to more business skewed towards the custom synthesis and higher production volumes from the validated projects (the margins more or less aligned with the covid reported trends). The Management expects the Ebitda margins to be similar to the last year though variations may happen on a quarterly basis. The other income is slightly lower and reported a drop of ~46% mainly due to the forex loss reported in Q1 as against a gain in previous quarter. The PAT registered a growth of ~65.5% on a y-o-y basis attributed to better topline and improved contribution margins. The **generics** business registered a growth of ~9.6% on a y-o-y basis whereas the **custom synthesis and nutraceuticals** reported a strong growth of ~45.8% and ~19.2% respectively on a y-o-y basis. Under the **custom synthesis** business, the capex projects are undergoing validation stages whereas for some the company has also been able to ship certain products to its customers. As far as the **peptides** segment is concerned, the Management is witnessing immense opportunities for fragments and couple of them are either under the pipeline/clinical phases/validation phase of development. Even though the generic business continued to face pricing pressure alongwith a substantial increase seen in the solvent raw material prices; based on the long-term contracts that it has, Divi's was in a position to increase the prices and pass on the same price hikes to its customers wherever possible. The Management anticipates to maintain a healthy product mix for its generics and custom synthesis business. The revenue guidance for FY27E is retained at **double digit** growth. In addition to the existing projects, the company has couple of other projects under its radar (which may not require large investments) which are expected in the subsequent quarters and would need validations as well from its customers. Overall, the progress across the business segment is pacing up in a gradual manner depending on the qualifications, approvals and commercialisation stages. With the limited upside to the current valuations as the mid to long term catalysts are largely factored in; **we maintain a neutral view on the stock for a revised target of Rs8500 (earlier target of Rs7950 has been achieved).**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Aether Industries Ltd **CMP: Rs1591** **Target: Rs1675**	The net sales for the quarter came in at Rs3266mn as compared to Rs2566mn in Q1FY26. The Ebitda margin for the quarter under review stood at 31.5% as compared to 31.6% in Q1FY26. The company reported a profit of Rs627mn as compared to Rs470mn in the same quarter last year. The EPS for the quarter stood at Rs4.77 as compared to Rs3.55 in the corresponding period of last year. **Outlook and Recommendations:** The company continues to be a high-growth specialty chemicals platform with significant long-term potential while reporting a good start to FY27 with an overall sales growth of 27% on a y-o-y basis. The performance is attributed towards the increased contribution from CRAMs and CEM business segments which are margin accretive for the company and on a quarterly basis the company has been in a position to convert more CRAMs relationships into long-term exclusive manufacturing contracts. The gross margins have seen an improvement and stood at ~49.8% for the quarter under review; this was on account of the company's ability to pass on the increase in the RM costs. The Ebitda margins stood flat when compared on a y-o-y basis at 31.5%; this was on account of higher staff cost and higher other expenses. In Q1FY27, the company received the balance settlement from the insurance company amounting to Rs260mn; of which Rs225mn was received for asset loss and Rs35mn for the Financial Loss/Profit (FLOP). The capacity additions at Site-4 and Site-5 combined with commercialization of new projects in semiconductors, material science and oil & gas can provide healthy growth visibility and opportunities. The Management aims to maintain the margins which are anticipated to be supported by improving product mix and higher utilization levels. The company has established several conversations and relationships with its customers spread across pharma, material science, petchem, oil & gas, etc. which is progressing well for the company. The Management expects to launch a couple of new products under the oil & gas and material science divisions in the subsequent quarters. The foray into the manufacturing of semicon materials that would be utilized in the 5G and AI supply chain serves as an immense opportunity for the company and is considered a high value, low volume product prospect that will be scaled up in a gradual manner by 2030. The company would also evaluate options to participate in the ISM 2.0 as well. Another important highlight for the quarter was the strategic partnership signed with Dow India for silicones which would progress and develop in a phased manner and is at present at a very nascent stage. The company has been diligently working on the customer concentration, incremental ROIC, working-capital intensity and execution risks associated with the aggressive expansion to fetch better returns. The next phase of value creation will entirely depend on the company's ability to generate attractive returns on the ~Rs3-3.5bn capex program as well as the improvement in cash conversion. Aether in the past has a record of already executing long term projects successfully and is anticipated to do the same in near future as well. **The stock has breached our target price of Rs1350, and considering the growth momentum, we have revised our estimates and projections; we have been conservative in our estimates and arrived at a target price of Rs1675.**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

Result Synopsis	
Company	**Result This Week**
Alembic Pharmaceuticals Ltd **CMP: Rs830** **Target: Rs900**	The net sales for the quarter grew by 25.7% at Rs21.50bn as compared to Rs17.11bn in the same quarter last year. The Ebitda margins for the quarter under review stood at 15.4% as compared to 16.4% in Q1FY26. The company reported profit of Rs1.73bn as compared to Rs1.54bn in the same quarter last year. The EPS for the quarter stood at Rs8.80 as compared to Rs7.85 in the corresponding period of last year. For Q1FY27, the India branded and US generics business reported growth of 7% and 49% respectively on a y-o-y basis. **<u>Outlook and Recommendations:</u>** The company has started FY27 on a strong note, delivering broad-based growth across different businesses. The performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The revenues reported growth of 25.7% y-o-y. **India** business reported growth of 7% y-o-y led by the robust growth across the therapies of gynaecology, gastrology and ophthalmology. The **Animal healthcare** segment also delivered encouraging performance during the quarter; accounting for 22% of the India business revenues. Growth is attributed to the expansion in the existing portfolio and better field force productivity. Excluding the vet business, India segment has underperformed the market growth; but is expected to be aligned with market growth in FY27E. Strong growth was reported by the 49% surge in **US formulation sales** and robust growth in the API segment, supported by new product launches and a healthy pipeline. The Management remains focused on building a differentiated portfolio in complex generics and specialty products, which could support gradual improvements in US business over the medium term. **Ex-US formulations** growth was 17% y-o-y with continued focus on expanding offerings and strengthening market reach. The API business reported strong growth of 33% y-o-y and the momentum is expected to continue going forward as well. The **gross margins** came in lower at 71.1% as the Middle East crisis led to uptick in solvent prices coupled with product mix and the debottlenecking taken up for the maintenance/upgrade of the ophthal line; shutdown was taken that led to under absorption of costs. The Management however feels 70-75% the range for gross margins in the near term. The **Ebitda margins** came in at 15.4% for the quarter; although on the lower side impacted by the expenses related to the branded business in the US; but in the trajectory of better operating leverage. The post R&D Ebitda increased 21% from the previous year; supported by operating leverage expansion amid planned strategic expansion in the US branded business and R&D pipeline focusing on peptide development and increased filings. The company has maintained the earlier target; with 16% in FY26 and the core will improve to high teens, offset by the margin dilution by US branded business by 150bps. The overall profits reported growth of 12.1% y-o-y. The company has revised the outlook towards the US business; announced plans to introduce more than 15 new products in the US market in FY27E. The new launches and the branded business would also start contributing in the next year to the overall US business growth. For the company as a whole, low double to mid teen range of growth is chalked on the revenues front in FY27E. Overall, growth ahead would be fuelled by new product launches and scaling up of existing products in focus markets of US and India coupled with meaningful investments in R&D. **We have achieved our target of Rs800 and recommend to book 15% profits for a revised target of Rs900.**

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

NIFTY (WEEKLY)

BANK NIFTY (WEEKLY)

MARKET OUTLOOK

As indicated in the previous weekly note, **Nifty50** has broken out of a Symmetrical Triangle Pattern, with a target of 26,850. Once the Index clears the primary hurdle at 24,700, it should open the door to 25,000; on the downside, 24,500 is the nearest support. **BankNifty** is finding it difficult to overcome the 58,100 hurdle, while 57,470 will serve as primary support. As noted in the previous report, the **Auto segment** and the recommended stocks performed as expected, so we remain positive on them. The ongoing correction in the **Capital Market Index** is likely to continue, as it has formed a bearish engulfing candlestick pattern. The **Defence segment** ended its month-long consolidation with a strong breakout, suggesting a resumption of its uptrend. The **Metal sector** breached its tight range to the upside, indicating a sustained upmove. A Symmetrical Triangle breakout was observed in the **PSU Banking segment**, while several constituents have also broken out from different patterns, pointing to trend continuation. After its stellar performance, the **Pharma sector** is consolidating; however, its primary uptrend remains intact.

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	0.36%
Adani Ports	0.09%
Apollo Hospital	0.04%
Asian Paints	(0.11%)
Axis Bank	0.89%
Bajaj Auto	1.24%
Bajaj Finserv	(1.09%)
Bajaj Finance	(5.54%)
BEL	3.40%
Bharti Airtel	(0.41%)
Cipla	(0.56%)
Coal India	0.21%
Dr. Reddy's Labs	2.31%
Eicher Motors	2.36%
Eternal	4.08%
Grasim	7.33%
HCL Tech	0.81%
HDFC Bank	(2.27%)

HDFC Life	(1.98%)
Hindalco	8.73%
HUL	(0.16%)
ICICI Bank	(0.89%)
Indigo	3.01%
INFY	4.00%
ITC	1.81%
JioFin	0.27%
JSW Steel	2.21%
Kotak Bank	0.49%
LT	3.00%
M&M	3.21%
Maruti	(1.43%)
Max Healthcare	(2.85%)
Nestle India	2.33%
NTPC	(1.18%)
ONGC	(1.42%)
PowerGrid	(4.43%)

Reliance	2.28%
SBI Life	(1.85%)
SBIN	6.77%
ShriRam Finance	6.58%
Sun Pharma	(2.11%)
Tata Consumer	0.02%
Tata Steel	(1.28%)
TCS	3.66%
Tech Mahindra	(1.14%)
TITAN	1.15%
TMPV	2.03%
Trent	(0.13%)
UltraTech	1.86%
Wipro	2.06%

SECTORAL PERFORMANCE



HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

SECTORAL GAINER

With gains of 5.01%, the **PSU Banking segment** outperformed the Benchmark Index. Except for **Maharashtra Bank (1.03%),** all the components ended the week with notable gains, where **Union Bank (+7.52%)** and **SBIN (+6.77%)** were the outperformers, subsequently by **Indian Bank (+6.64%)** and **Canara Bank (+5.64%).** As shown in the chart, the sector has given a breakout from a **Symmetrical Triangle Pattern, while several counters have also given a breakout, indicating a bullish trend continuation**.

SECTORAL LOSER

The **Media segment** lagged Nifty50, declining 3.94%. Heavyweight **Zee Entertainment** took the biggest hit, **tumbling 17.63%**, followed by **Sun TV,** which fell **4.27%**. On the other hand, **Nazara and PVR Inox** advanced **3.96% and 3.02%**, respectively.

HIGHLIGHTS OF THE WEEK 03 Aug 2026-07 Aug 2026

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai-400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500

Grievance Officer:
Email: grievancecell@progressiveshares.com